Category: 3. Business

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) — Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company that focuses on RNA and gene therapies for the treatment of rare diseases. During the class period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy (“Duchenne”), including ELEVIDYS. ELEVIDYS is a prescription gene therapy intended for a limited category of people with Duchenne.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug

According to the complaint, during the class period, defendants failed to disclose that: (i) ELEVIDYS posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; and (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals.

Plaintiff alleges that on March 18, 2025, Sarepta issued a safety update on ELEVIDYS announcing that a patient had died following treatment with ELEVIDYS. On this news, Sarepta’s stock price fell $27.81 per share, or 27.44%, to close at $73.54 per share on March 18, 2025. Then, on June 15, 2025, Sarepta disclosed a second patient had died of acute liver failure following treatment with ELEVIDYS. The Company announced it was suspending shipments of ELEVIDYS for non-ambulatory patients while Sarepta took time to evaluate trial regimens and discussed findings with regulatory authorities. Sarepta also revealed that it was pausing dosing in one of its ELEVIDYS clinical studies. On this news, Sarepta’s stock price fell $15.24 per share, or 42.12%, to close at $20.91 per share on June 15, 2025.

Finally, on June 24, 2025, the FDA announced it was investigating the risk of acute liver failure with serious outcomes following treatment with ELEVIDYS. On this nes, Sarepta’s stock price fell $1.52 per share, or 8.01%, to close at $17.46 per share on June 25, 2025.

What Now: You may be eligible to participate in the class action against Sarepta Therapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class must file a motion for lead plaintiff by August 25, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.  

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Sarepta Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

And as PYMNTS reported last month, Apollo Global Management is working with five banks, including JPMorgan Chase & Co. and Goldman Sachs Group, to trade private credit.

As the lines blur in financial services, and traditional banking players link with nonbanks to expand credit, so too is there a blurring of the nomenclature of those efforts, referred to variously as shadow banking or nonbank financial intermediation.

Data found in this Monday (June 30) post by the St. Louis Federal Reserve underscore the magnitude of exposure. As measured at the end of the first quarter of 2025, U.S. banks held $1.14 trillion in loans outstanding to the nonbank financial sector.

“This interconnectedness between banks and nonbanks adds an extra layer of intermediation, as banks lend to mortgage companies, insurance companies, investment funds (such as mutual funds, money market funds, hedge funds and private capital funds), pension funds, broker-dealers, securitization vehicles and other financial entities, which then lend directly to end users in the economy,” noted the Fed. The growth rate of non-depository financial institutional lending has grown by 26% on average each year since 2012.

Getting a bit more granular, the Financial Stability Board estimated late last year that the aggregate FinTech lending across seven jurisdictions came in at $38.5 billion.

As the FSB elaborated, “FinTech lending platforms can act as auxiliaries or intermediaries. As auxiliaries, they can be in the form of a ‘marketplace platform,’ which is an online market that allows lenders to trade directly with borrowers (peer-to-peer lending and crowdfunding platforms). Fintech lending platforms can act as intermediaries when they use their balance sheets to originate the lending.”

Loans to mortgage and private credit intermediaries each represent 23% of loans outstanding, and loans to business intermediaries and consumer intermediaries represent 21% and 9%, respectively, estimated the Fed.

Risks of ‘Runnable’ Activity

In separate data and analysis as of last week, according to a report by the Congressional Research Service, “banks are increasingly lending to NBFIs (nonbank financial institutions) and, at the same time, reducing their lending to commercial and industrial borrowers.”

“Increased lending from banks to NBFIs could expose banks to counterparty credit risk and spillover effects during a financial crisis…” the report added. “The size and growth of NBFI suggest that significant amount of financing is being intermediated and held outside of the banking sector. In contrast to the traditional banking model, where banks normally manage risks (e.g., credit, market, liquidity, and operational risks) on their balance sheets, the market-based NBFI financing model shifts risks toward capital markets investors and intermediaries.”

As for the risks, the CRS cautioned that the “vulnerabilities affecting financial stability are present in capital markets NBFI, including in certain money-like instruments that face potential ‘runs,’ leverage levels, interconnectedness between nonbanks and banks, data and transparency issues, liquidity mismatch at certain open-end funds, and concentration risk at market intermediaries.”

There’s a knock-on effect here, as some financial institutions are grappling with shadow banking stalwarts as competitors, which in turn has shifted activities away from core deposits toward long-term securities and other holdings. In this paper from economists at the Fed and at the University of Houston, there’s the contention that in doing so, net interest income margins are pressured.

Lundin Mining Announces Updated Share Capital, Provides Update on Share Buybacks and Announces Filing of ESTMA Report and Modern Slavery Report

June 30, 2025

VANCOUVER, BC, June 30, 2025 /CNW/ – (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation (“Lundin Mining” or the “Company”) reports the following updated share capital and voting rights, in accordance with the Swedish Financial Instruments Trading Act. View PDF.

The number of issued and outstanding shares of the Company has increased by 179,029 to 855,997,663 common shares with voting rights as of June 30, 2025. The increase in the number of issued and outstanding shares from May 31, 2025 to date is a result of the exercise of employee stock options or the vesting of employee share units. During this period, the Company did not purchase any shares for cancelation under its Normal Course Issuer Bid program.

Normal Course Issuer Bid

Under the Company’s shareholder distribution policy, the Company is committed to allocating up to US$150 million in annual share buybacks through the NCIB program. So far during 2025, Lundin Mining has acquired 12,629,000 common shares at a cost of approximately US$104 million.

ESTMA Report and Modern Slavery Report

Lundin Mining has filed its ESTMA Report and Modern Slavery Report for the year ended December 31, 2024, which can be found on the Company’s website (lundinmining.com).

About Lundin Mining

Lundin Mining is a diversified base metals mining company with operations or projects in Argentina, Brazil, Chile, and the United States of America, primarily producing copper, gold and nickel.

The information in this release is subject to the disclosure requirements of Lundin Mining under the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out below on June 30, 2025 at 16:00 Pacific Time.

SOURCE Lundin Mining Corporation

For further information, please contact: Stephen Williams, Vice President, Investor Relations: +1 604 806 3074; Robert Eriksson, Investor Relations Sweden: +46 8 440 54 50